DiaMedica Therapeutics to Report Third Quarter 2020 Financial Results and Provide a Business Update November 5, 2020
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) will release its third quarter 2020 financial results after market close on November 4, 2020. A conference call to discuss these results will be held on November 5, 2020, at 7:00 AM CT. Investors can join the call via dial-in or webcast, with replay options available until November 12, 2020. DiaMedica is focused on developing treatments for chronic kidney diseases and neurological disorders.
- Scheduled release of Q3 2020 financial results may indicate progress towards improving investor confidence.
- Focus on chronic kidney diseases and neurological disorders aligns with significant market needs.
- None.
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that its third quarter 2020 financial results will be released after the markets close on Wednesday, November 4th. DiaMedica will host a live conference call on Thursday, November 5th at 7:00 AM Central Time to discuss its business update and financial results.
Conference Call details:
Date: |
Thursday, November 5, 2020 |
|
Time: |
7:00 AM CT / 8:00 AM ET |
|
Web access: |
https://event.on24.com/wcc/r/2623032/5A77F53289171F7E16245B392065B627 | |
Dial In: |
(866) 393-4306 (domestic) |
|
(734) 385-2616 (international) |
||
Conference ID: |
4869514 |
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for play back on DiaMedica’s website, under investor events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until November 12, 2020, by dialing (855) 859-2056 (US Toll Free), (404) 537-3406 (International), replay passcode 4869514.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
